Diabetes risk score: Towards earlier detection or type 2 diabetes in general practice

Diabetes/Metabolism Research and Reviews

Volumn 16, Issue 3, 2000, Pages 164-171

  Griffin, S J ^a,d   Little, P S ^b   Hales, C N ^c   Kinmonth, A L ^a   Wareham, N J ^d  

^a Forvie Site   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

General practice; Risk score; Screening; Type 2 diabetes

Indexed keywords

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; GENDER; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; STATISTICS; STEROID THERAPY; TISSUE INJURY;

DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RISK FACTORS; TIME FACTORS;

EID: 0034084854     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>3.0.CO;2-R     Document Type: Article

References (76)

1. McCarty D, Zimmet P. Diabetes 1994 to 2010: Global Estimates and Projections. International Diabetes Institute: Melbourne, 1994.
2. Neil HAW, Mather HM, Thompson QV, Thorogood GH, Fowler GH, Hill RD. The Oxford Community Diabetes Study: evidence for an increase in the prevalence of known diabetes in Great Britain. Diabet Med 1987; 4: 539-543.
3. King's Fund Policy Institute. Counting the Cost: the Real Impact of Non-Insulin-Dependent Diabetes Mellitus. British Diabetic Association: London, 1997.
4. Jackson DMA, Wills R, Davies J, Meadows K, Singh BM, Wise PH. Public awareness of the symptoms of diabetes mellitus. Diabet Med 1991; 8: 971-972.
5. Goyder EC, McNally PG, Drucquer M, Spiers N, Botha JL. Shifting of care for diabetes from secondary to primary care, 1990-5: review of general practices. BMJ 1998; 316: 1505-1506.
6. Cowie C, Harris MI, Eberhardt MS. Frequency and determinants of screening for diabetes in the U.S. Diabetes Care 1994; 17: 1158-1163.
7. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16: 642-652.
8. Harris MI, Klein R, Wellborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
9. UK Prospective Diabetes Study Group. UK prospective diabetes study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res Clin Pract 1990; 13: 1-11.
10. UK Prospective Diabetes Study Group. UKPDS VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-890.
11. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
12. Guillausseau P-J, Massin P, Charles M-A, Allaguy H, Guvenli Z, Virally M, et al. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabet Med 1998; 15: 151-155.
13. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
16. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
17. Davies MJ, Grenfell A, Day JL. Clinical characteristics and follow-up of subjects with non-insulin-dependent diabetes mellitus diagnosed by screening. Prac Diab Int 1996; 13: 75-78.
18. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
19. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
20. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
21. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
22. Wilson JGM, Jungner G. Principles and Practice of Screening for Disease. World Health Organization: Geneva, 1968.
23. Engelgau MM, Aubert RE, Thompson TJ, Herman WH. Screening for NIDDM in nonpregnant adults: a review of principles, screening tests, and recommendations. Diabetes Care 1995; 18: 1606-1617.
24. National Screening Committee. First Report of the National Screening Committee. Health Departments of the United Kingdom: London, 1998.
25. Davies MJ, Williams DRR, Metcalfe J, Day JL. Community screening for non-insulin-dependent diabetes mellitus: self-testing for post-prandial glycosuria. QJM 1993; 86: 677-684.
26. Bullimore SP, Keyworth C. Finding diabetics - a method of screening in general practice. Br J Gen Pract 1997; 47: 371-374.
27. Falkenberg M, von Schenck H. Screening for diabetes mellitus using a self-administered blood spottest mailed for analysis. Pract Diabetes 1988; 5: 159-160.
28. OPCS. General Household Survey. HMSO: London, 1992
29. Williams DRR, Wareham NJ, Brown DC, Byrne CD, Clark PMS, Cox BD, et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabet Med 1995; 12: 30-35.
30. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. WHO: Geneva, 1985.
31. Kinmonth A-L, Spiegal N, Woodcock A. Developing a training programme in patient-centred consulting for evaluation in a randomised controlled trial; diabetes care from diagnosis in British primary care. Patient Educ Couns 1996; 29: 75-86.
32. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
33. Gardner MJ, Altman DG. Statistics with Confidence. British Medical Association: London, 1989.
34. Armitage P, Berry G. Sampling. In Statistical Methods in Medical Research, Armitage P, Berry G (eds). Blackwell Science: Oxford, 1994; 78-92.
35. General Medical Services Committee. The New Health Promotion Package. British Medical Association: London, 1993.
36. Engelgau MM, Thompson TJ, Smith PJ, Herman WH, Aubert RE, Gunter EW, et al. Screening for diabetes mellitus in adults. The utility of random capillary blood glucose measurements. Diabetes Care 1995; 18: 463-466.
37. 1 and fructosamine in diagnosis of glucose-tolerance abnormalities. Diabetes Care 1990; 13: 898-900.
38. Forrest RD, Jackson CA, Yudkin JS. The glycohaemoglobin assay as a screening test for diabetes mellitus: The Islington Diabetes Survey. Diabet Med 1987; 4: 254-259.
39. Hanson RL, Nelson RG, McCance DR, Beart JA, Charles MA, Pettitt DJ, et al. Comparison of screening tests for non-insulin-dependent diabetes mellitus. Arch Intern Med 1993; 153: 2133-2140.
40. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 1997; 20: 491-496.
41. Burden ML, Burden AC. The American Diabetes Association screening questionnaire for diabetes. Is it worthwhile in the UK? Diabetes Care 1994; 17: 97.
42. Baan CA, Ruige JB, Stolk RP, Witteman JC, Dekker JM, Heine RJ, et al. Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 1999; 22: 213-219.
43. Anonymous. Screening brief. Antenatal screening for Down's syndrome. J Med Screen 1995; 2: 56.
44. Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999; 83: 660-666.
45. Andersson DKG, Lundblad E, Svardsudd K. A model for early diagnosis of Type 2 diabetes mellitus in primary health care. Diabet Med 1993; 10: 167-173.
46. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
47. Meltzer S, Leiter L, Daneman D, Gertsein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998; 159: S1-29.
48. Welborn TA, Reid CM, Marriott G. Australian diabetes screening study: impaired glucose tolerance and non-insulin-dependent mellitus. Metabolism 1997; 46: 35-39.
49. Fairley R. Audit report. How effective is case finding at detecting diabetes and hypertension in the community? BMJ 1987; 294: 1202
50. Worrall G. Screening healthy people for diabetes: Is it worthwhile? J Fam Pract 1991; 33: 155-160.
51. UK Prospective Diabetes Study Group. UK prospective diabetes study XII: differences between Asian, Afro-Caribbean and White Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabet Med 1994; 11: 670-677.
52. de Courten M, Zimmet P. Screening for non-insulin-dependent diabetes mellitus: where to draw the line. Diabet Med 1997; 14: 95-98.
53. Simmons D, Williams DR, Powell MJ. Prevalence of diabetes in a predominantly Asian community: preliminary findings of the Coventry diabetes study. BMJ 1989; 298: 18-21.
54. Van Drenth BB, Hulscher MEJL, Van der Wouden JC, Mokkink HGA, Van Weel C, Grol RPTM. Relationship between practice organization and cardiovascular risk factor recording in general practice. Br J Gen Pract 1998; 48: 1054-1058.
55. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998; 351: 689-690.
56. Harris MI, Modan M. Screening for NIDDM. Why is there no national program? Diabetes Care 1994; 17: 440-444.
57. Field K, Thorogood M, Silagy C, Normand C, O'Neill C, Muir J. Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ 1995; 310: 1109-1112.
58. Singh BM, Jackson DMA, Wills R, Davies J, Wise PH. Delayed diagnosis in non-insulin dependent diabetes mellitus. BMJ 1992; 304: 1154-1155.
59. Camerini-Davalos RA, Velasco C, Glasser M, Bloodworth JM Jr. Drug-induced reversal of early diabetic microangiopathy. N Engl J Med 1983; 309: 1551-1556.
60. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 1997; 20: 537-544.
61. Eriksson K-F, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1991; 34: 891-898.
62. Sartor G, Scherstén B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41-49.
63. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
64. Segal L, Dalton AC, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promotion Int 1998; 13: 197-209.
65. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 1982; 31(Suppl. 5): 1-81.
66. Kerbel D, Glazier R, Holzapfel S, Yeung M, Lofsky S. Adverse effects of screening for gestational diabetes: a prospective cohort study in Toronto, Canada. J Med Screen 1997; 4: 128-132.
67. Genuth SM, Houser HB, Carter JR Jr, Merkatz IR, Price JW, Schumacher OP, et al. Observations on the value of mass indiscriminate screening for diabetes mellitus based on a five-year follow-up. Diabetes 1978; 27: 377-383.
68. Marteau TM. Psychological costs of screening. BMJ 1989; 299: 527.
69. Meland E, Laerum E, Maeland JG. Life style intervention in general practice: effects on psychological wellbeing and patient satisfaction. Qual Life Res 1996; 5: 348-354.
70. Marteau TM, Kinmonth AL, Thompson S, Pyke S. The psychological impact of cardiovascular screening and intervention in primary care: a problem of false reassurance? Br J Gen Pract 1996; 46: 577-582.
71. Johnston ME, Gibson ES, Terry CW, Haynes RB, Taylor DW, Gafni A, et al. Effects of labelling on income, work and social function among hypertensive employees. J Chron Dis 1984; 37: 417-423.
72. Stewart-Brown S, Farmer A. Screening could seriously damage your health. BMJ 1997; 314: 533-534.
73. Kinlay S, Heller RF. Effectiveness and hazards of case finding for a high cholesterol concentration. BMJ 1990; 300: 1545-1547.
74. Irvine MJ, Logan AG. Is knowing your cholesterol number harmful? J Clin Epidemiol 1994; 47: 131-145.
75. Robertson I, Phillips A, Mant D, Thorogood M, Fowler G, Fuller A, et al. Motivational effect of cholesterol measurement in general practice health checks. Br J Gen Pract 1992; 42: 469-472.
76. Yudkin JS, Alberti KGMM, McLarty DG, Swai ABM. Impaired glucose tolerance. BMJ 1990; 301: 397-402.